CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. Its business is straightforward: it manufactures and markets consumer and professional products through a portfolio that includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita and Burt’s Bees on the consumer side, and Purell, CloroxPro and Clorox Healthcare on the professional side. According to its most recent 10-K, fiscal 2026 net sales reached $6.7 billion, generated by roughly 9,200 employees operating in about 25 countries and selling into roughly 95 markets. The company is therefore a broadly diversified household staples operator, not a single-product bleach story.

The margin profile supports the “staples” interpretation. The net margin is 8.7%, which is respectable for a mature household-products peer set but not eye-catching; it suggests pricing power is present yet constrained by private-label competition and input-cost volatility. The ROE figure of -1,893.5% is the most jarring number in the financial snapshot. Negative equity of this magnitude is almost certainly driven by a debt-financed share-buyback program that pushed equity deep into negative territory, not by operational insolvency. In that context, ROE is mathematically distorted and should not be read as evidence of weak moat. A better competitive read comes from the 8.7% net margin and the brand portfolio: the company owns category-leading names with repeat-purchase behavior, which is exactly the kind of intangible moat household-products investors look for. Still, with Walmart alone accounting for 26% of consolidated FY2026 net sales and the top five customers representing about half of sales, customer concentration is a structural risk that even strong brands cannot fully negate.

Financial posture

As of the snapshot date, Clorox carried a $10.2 billion market capitalization and traded at a 17.6x trailing P/E, a valuation that sits at a modest discount to many consumer-staples peers and implies the market has priced in the current earnings reset. The 8.7% net margin is consistent with a company digesting cost inflation and a major operational transition, while the 0.57 beta flags the stock as a low-volatility, defensive holding relative to the broader market.

Again, the -1,893.5% ROE demands context. Clorox has long carried shareholder equity near or below zero because buybacks and dividends have exceeded retained earnings over time. That makes ROE an unusable standalone profitability metric here; it does not mean the business is loss-making. The P/E of 17.6x confirms the market is treating the current earnings as positive and sustainable enough to assign a mid-teens multiple. Investors should therefore focus on free-cash-flow generation, net debt and interest coverage rather than ROE when assessing financial health. The fiscal 2026 diluted EPS decline of 26%, noted in the 10-K, explains why the multiple is compressed relative to historical averages: this is a company whose profitability has reset lower.

Strategic priorities & outlook

The most recent 10-K frames Clorox’s near-term agenda around the IGNITE strategy, built on four pillars: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Those priorities translate into three concrete operational workstreams.

First, Clorox is midstream on a large enterprise resource planning (ERP) system and broader digital transformation, which it expects to drive long-term efficiencies across supply chain, digital commerce, innovation and brand building. Second, it is investing in brand strength, digital capabilities and a streamlined operating model to create what management calls a more resilient company capable of consistent, profitable growth. Third, it is advancing health and hygiene expansion, including the integration of GOJO Industries, which it acquired in April 2026. The GOJO deal directly supports the professional and institutional markets and widens the business-to-business footprint. The 10-K also notes that fiscal 2026 organic sales and earnings declined, with diluted EPS down 26%, partly because ERP transition timing had pulled some sales forward into fiscal 2025 and because macroeconomic headwinds weighed on demand. In other words, management is asking investors to look through a transition year while the GOJO integration and ERP rollout mature.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox sits in a sector with several predictable macro sensitivities. Input-cost inflation is the most direct concern: resin, paper, chemicals, packaging and transportation costs are all significant inputs for cleaning, bags, wraps, cat litter and personal-care products. When commodity prices spike, margins compress unless price increases stick, and those same price increases can dampen volume, especially in a slower consumer-spending environment. Currency translation matters given the roughly 95 markets where products are sold; a stronger U.S. dollar reduces the value of overseas earnings. Trade policy and tariffs are relevant because many raw materials and finished goods move across borders, and any broad tariff regime can raise input costs or disrupt supply chains. Regulatory exposure also runs through the sector, including EPA oversight for disinfectants, FDA and FTC rules for personal-care claims, and plastic-waste and packaging regulations that increasingly affect single-use products like Glad bags and Fresh Step litter. Finally, the customer-concentration pattern seen in the filing—Walmart at 26% and the top five customers near half of sales—is common in consumer packaged goods and means pricing negotiations with a handful of retailers can meaningfully move the top line.

Recent developments

The most recent news flow has been light on operational更新 and heavy on portfolio-manager positioning. On October 19, 2026, Defense World reported the State of Alaska Department of Revenue increased its Clorox holdings. One day earlier, on October 18, 2026, the same outlet noted that Birch Hill Investment Advisors LLC sold 11,260 shares of Clorox. Those two headlines, taken together, show ordinary rebalancing activity rather than a directional institutional verdict. Also on October 18, 2026, The Motley Fool listed Clorox among five dividend stocks trading near 52-week lows that the author would hold for the next five years. On October 13, 2026, 24/7 Wall St. included Clorox in a list of six dividend stocks that “look like income bargains,” while cautioning that their payout ratios suggested otherwise. None of these items reported new company-specific developments; they simply reflect the debate around whether Clorox’s yield and valuation are attractive enough to offset the earnings headwinds.

Earnings behavior & post-earnings drift

Clorox has a respectable recent earnings record. Over the last eight reported quarters, the company beat estimates six times, for a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day post-earnings price move across those quarters was 1.67% to the upside, which classifies the post-earnings drift direction as “up.” That pattern suggests that, on balance, Clorox has delivered results marginally better than the sell-side estimate and that the stock has tended to drift higher in the days that follow.

Yet the most recent quarters show a more mixed picture and reveal the limits of averages. In the August 3, 2026 report, Clorox delivered EPS of $1.66 against an estimate of $1.64, a 1.2% beat, and the stock rose 6.52% the next session and 9.61% over the following five days. By contrast, the April 30, 2026 report was a larger 5.8% beat, $1.64 versus $1.55, but the stock fell 9.67% the next day and 4.49% over the next five days, likely because guidance or commentary offset the headline beat. The February 3, 2026 quarter was a 2.8% miss, $1.39 versus $1.43, yet the stock gained 2.43% the next day and 5.63% over five days, hinting that the market’s real expectation may have been even lower than the published estimate. The November 3, 2025 report was a 3.9% beat, $0.85 versus $0.818, with a muted 1.17% next-day gain but a 4.08% five-day decline. In short, the post-earnings reaction function is not mechanical; beats do not guarantee gains, and misses do not guarantee losses. The next earnings report is scheduled for November 2, 2026, after the close, with the consensus EPS estimate at $1.08. Traders watching for continuation should remember that the 1.67% average positive five-day drift is only an average and that the last four reports have produced both outsized rallies and sharp drawdowns after initially favorable prints.

For a deeper dive into how sell-side analysts and institutional investors are interpreting these transition dynamics ahead of the November 2, 2026 report, readers should review the full institutional verdict available on the platform.